# The US Supreme Court rejected a series of appeals from several of the nation's largest drugmakers.

*biotech · news · 2026-05-18 · Cable News Network*

## Key points

- The Supreme Court rejected multiple drugmaker appeals challenging Medicare price negotiation requirements.
- Medicare's drug negotiation program is projected to save $6 billion in its first round alone.
- Lower courts held that drugmakers can withdraw from Medicare if they oppose negotiated prices.
- AstraZeneca said its drug Farxiga received a 68% price cut through the negotiation process.
- No lower court has supported drugmakers' constitutional claims against the negotiation program so far.

**Companies:** Bristol Myers Squibb, AstraZeneca, Janssen
**Countries:** United States

[Read the full story on Cable News Network](https://edition.cnn.com/2026/05/18/politics/drug-prices-supreme-court-medicare)

---

Canonical: https://newsio.io/n/2bd45774-5ad4-45e0-a827-32c2f9d9f639/the-us-supreme-court-rejected-a-series-of-appeals-from-several-of-the-nations-la
Summarized by Newsio from Cable News Network. https://newsio.io/how-it-works